In the past week, IMMP stock has gone up by 24.34%, with a monthly gain of 12.40% and a quarterly surge of 31.92%. The volatility ratio for the week is 10.00%, and the volatility levels for the last 30 days are 7.88% for Immutep Limited ADR The simple moving average for the past 20 days is 14.02% for IMMP’s stock, with a 30.54% simple moving average for the past 200 days.
Is It Worth Investing in Immutep Limited ADR (NASDAQ: IMMP) Right Now?
The 36-month beta value for IMMP is at 2.14. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMMP is 115.40M, and currently, shorts hold a 1.09% of that float. The average trading volume for IMMP on April 24, 2024 was 140.84K shares.
IMMP) stock’s latest price update
The stock price of Immutep Limited ADR (NASDAQ: IMMP) has surged by 11.95 when compared to previous closing price of 2.51, but the company has seen a 24.34% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-01-03 that Immutep Limited’s lead molecule, eftilagimod, has shown signals of activity in lung cancer and has the potential to be a chemotherapy-free regimen with manageable toxicity. The company has received regulatory feedback on the design of a registrational trial for eftilagimod, indicating progress in its development. Immutep has a fairly strong financial position with $110 million AUD in cash and equivalents, providing them with several quarters of operational runway.
Analysts’ Opinion of IMMP
Many brokerage firms have already submitted their reports for IMMP stocks, with Robert W. Baird repeating the rating for IMMP by listing it as a “Outperform.” The predicted price for IMMP in the upcoming period, according to Robert W. Baird is $7 based on the research report published on August 03, 2023 of the previous year 2023.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see IMMP reach a price target of $8.30. The rating they have provided for IMMP stocks is “Buy” according to the report published on August 03rd, 2021.
Maxim Group gave a rating of “Buy” to IMMP, setting the target price at $8 in the report published on July 16th of the previous year.
IMMP Trading at 15.22% from the 50-Day Moving Average
After a stumble in the market that brought IMMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.95% of loss for the given period.
Volatility was left at 7.88%, however, over the last 30 days, the volatility rate increased by 10.00%, as shares surge +18.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.73% upper at present.
During the last 5 trading sessions, IMMP rose by +25.44%, which changed the moving average for the period of 200-days by +33.73% in comparison to the 20-day moving average, which settled at $2.49. In addition, Immutep Limited ADR saw 17.08% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IMMP
Current profitability levels for the company are sitting at:
- -12.49 for the present operating margin
- 0.49 for the gross margin
The net margin for Immutep Limited ADR stands at -10.88. The total capital return value is set at -0.6. Equity return is now at value -41.05, with -37.64 for asset returns.
Based on Immutep Limited ADR (IMMP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.87. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -2250.16.
Currently, EBITDA for the company is -42.88 million with net debt to EBITDA at 1.52. When we switch over and look at the enterprise to sales, we see a ratio of 64.45. The receivables turnover for the company is 0.91for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.24.
Conclusion
In conclusion, Immutep Limited ADR (IMMP) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
